Bing Han | Health and Medicine Advances | Best Researcher Award

Dr. Bing Han | Health and Medicine Advances | Best Researcher Award

Postdoctoral Researcher, The First Affiliated Hospital of Zhengzhou University, China

Dr. Bing Han, Professor at The First Affiliated Hospital of Zhengzhou University, China, is an accomplished medical scientist and clinician whose research bridges molecular biology, microbiome science and clinical gastroenterology. He earned his medical degree (M.D.) followed by postdoctoral research training focused on digestive disease mechanisms and microbial interactions, establishing a strong foundation in translational and precision medicine. His primary research interests center on the gut microbiota–host interaction, bile acid metabolism, intestinal inflammation and biomarker discovery for digestive disorders, with emerging interests in microbiome-based therapeutic interventions. Over his distinguished career, Dr. Bing Han has held academic and clinical roles at The First Affiliated Hospital of Zhengzhou University and collaborated with The First Affiliated Hospital of the University of Science and Technology of China, contributing to interdisciplinary advancements in medical research. His key scientific contributions include innovative studies on the mechanisms of fecal microbiota transplantation in improving inflammatory bowel disease (IBD) and the development of biomedical devices such as spinal positioning systems and femoral defect fixation stents. He has published 9 scientific documents, receiving 50 citations with an h-index of 5 and authored the academic book Frontiers of Tumor Research. Among his notable research supports are the China Postdoctoral Science Foundation Grant, National Natural Science Foundation of China Grant and the Guangxi Natural Science Foundation and Health Commission Projects of Guangxi Zhuang Autonomous Region. His professional engagements include serving as a Young Editorial Board Member for the Journal of Guangxi Medical University and membership in the Digestive Professional Committee of the Chinese Society of Pathophysiology and the Gut Microbiota Branch of the Chinese Society of Biophysics. Through his pioneering research on gut microbiota and digestive pathophysiology, Dr. Bing Han aims to revolutionize clinical diagnostics and therapeutics, promoting global health advancement and innovation in biomedical science.

Profile: Scopus | ORCID | ResearchGate

Featured Publications

1. Han, B., Tang, D., Zhu, H., et al. (2024). Integrated multi-omics reveal gut microbiota-mediated bile acid metabolism regulating immunotherapy responses to anti-α4β7-integrin in Crohn’s disease. Gut Microbes, 16(1), 2310894.

2. Han, B., Li, C., Meng, H., et al. (2019). Efficacy and safety of external-beam radiation therapy for hepatocellular carcinoma: An overview of current evidence according to the different target population. Bioscience Trends, 13(1), 10–22.

3. Han, B., Tang, D., Lv, X., et al. (2023). Comparative efficacy and safety of combination therapy with infliximab for Crohn’s disease: A systematic review and network meta-analysis. International Journal of Colorectal Disease, 38(1), 82.

4. Han, B., Shao, L., Li, C., et al. (2019). Surgery versus external beam radiation therapy for AJCC stage I hepatocellular carcinoma. Journal of BUON, 24(4), 1390–1401.

5. Han, B., Yao, H., Shao, L., et al. (2018). Selection of treatment modalities for hepatocellular carcinoma at stages T1 and T2: A preliminary analysis based on the Surveillance, Epidemiology, and End Results registry database. Journal of BUON, 23(3), 611–621.

 

Jie Wu | Health and Medicine | Best Researcher Award

Prof. Dr. Jie Wu | Health and Medicine | Best Researcher Award

Professor and Lab Director, Shantou University Medical College, China

Prof. Dr. Jie Wu is a Distinguished Professor and Director of the Laboratory of Brain Function and Disease at Shantou University Medical College, China, and formerly served as Professor and Director of the Neurophysiology Laboratory at the Barrow Neurological Institute (BNI), St. Joseph’s Hospital and Medical Center, USA. He earned his M.D. from Xuzhou Medical College in 1983 and Ph.D. in Neurophysiology from Sun Yat-sen University of Medical Sciences in 1990, followed by postdoctoral fellowships at Tohoku University School of Medicine, Japan (1993–1994), and the University of New Mexico, USA (1994–1997). His research focuses on the physiology and pharmacology of nicotinic acetylcholine receptors (nAChRs), molecular mechanisms of epilepsy, and neurodegenerative disorders related to amyloid beta (Aβ) and receptor dysfunction, as well as ATP-sensitive potassium (KATP) channel regulation. Over three decades, he has led groundbreaking neuroscience research funded by the U.S. National Institutes of Health (NIH), the State of Arizona, and various international foundations, making fundamental discoveries in synaptic receptor signaling and neurodegeneration. His pioneering contributions have led to nearly 200 peer-reviewed publications, five book chapters, and eight patents (four U.S. and four Chinese), providing novel insights into receptor-mediated neurological diseases and translational therapies. Among his many honors, Prof. Dr. Jie Wu has received the China National Natural Science Award and the International HH Rosenfield Rekate Pioneer Award, and was listed among the World’s Top 2% Scientists (2022) and elected as a Fellow of the Royal Society of Arts (FRSA, UK, 2024). He serves as Editor-in-Chief and editorial board member for leading international journals and is active in global neuroscience and biomedical societies. With 161 documents, 5,887 citations and an h-index of 44, Prof. Dr. Jie Wu exemplifies research excellence and leadership, advancing global neuroscience through innovation, collaboration, and mentorship that continues to shape the future of brain science and human health worldwide.

Profile: Scopus | ORCID | Google Scholar | ResearchGate | Sci Profiles | Loop | LONGDOM | LinkedIn 

Featured Publications

1. Zhang, X. X., Gao, M., Liu, Q. R., Bi, G. H., Li, X., Yang, H. J., Gardner, E. L., & Wu, J. (2014). Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proceedings of the National Academy of Sciences of the United States of America, 111(46), E5007–E5015.

2. Liu, Q., Huang, Y., Xue, F., Simard, A., DeChon, J., Li, G., Zhang, J., Lucero, L., & Wu, J. (2009). A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. Journal of Neuroscience, 29(4), 918–929.

3. Wang, T. N., Yang, W., Wang, Y., Nagaraj, V. J., Liu, Q., & Wu, J. (2012). Label-free measuring and mapping of binding kinetics of membrane proteins in single living cells. Nature Chemistry, 4(10), 846–853.

4. Chen, D. J., Gao, M., Gao, F. F., Su, Q. X., & Wu, J. (2017). Brain cannabinoid receptor 2: Expression, function and modulation. Acta Pharmacologica Sinica, 38(3), 312–316.

5. Okada, Y. C., Wu, J., & Kyuhou, S. (1997). Genesis of MEG signals in a mammalian CNS structure. Electroencephalography and Clinical Neurophysiology, 103(4), 474–485.